[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Drugs for Schistosomiasis Industry Research Report 2024

April 2024 | 123 pages | ID: D9DFF353730FEN
APO Research

US$ 2,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Schistosomiasis, also known as snail fever and bilharzia, is a disease caused by parasitic flatworms called schistosomes. The urinary tract or the intestines may be infected. Signs and symptoms may include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, it may cause poor growth and learning difficulty.

According to APO Research, the global Drugs for Schistosomiasis market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of xx% during the forecast period 2024-2030.

Shin Poong, Merck, Bayer, EIPICO, Chandra Bhagat Pharma and Taj Pharmaceuticals are the main manufacturers of drugs for Schistosomiasis.

East Africa is the largest region of drugs for Schistosomiasis, whose market share is about 24%,

Followed by West Africa(20%).

Report Scope

This report aims to provide a comprehensive presentation of the global market for Drugs for Schistosomiasis, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Drugs for Schistosomiasis.

The report will help the Drugs for Schistosomiasis manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Drugs for Schistosomiasis market size, estimations, and forecasts are provided in terms of sales volume (M Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Drugs for Schistosomiasis market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2019-2024. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:
  • Shin Poong
  • Merck
  • Bayer
  • EIPICO
  • Chandra Bhagat Pharma
  • Taj Pharmaceuticals
Drugs for Schistosomiasis segment by Type
  • Praziquantel
  • Oxamniquine
  • Other
Drugs for Schistosomiasis segment by Application
  • S. haematobium
  • S. mansoni
  • S. japonicum
  • S. mekongi
  • S. intercalatum
Drugs for Schistosomiasis Segment by Region
  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Russia
  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • India
  • Australia
  • China Taiwan
  • Indonesia
  • Thailand
  • Malaysia
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Schistosomiasis market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Schistosomiasis and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Schistosomiasis.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Drugs for Schistosomiasis manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Drugs for Schistosomiasis by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Drugs for Schistosomiasis in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

Chapter 11: The main points and conclusions of the report.
1 PREFACE

1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
  1.5.1 Secondary Sources
  1.5.2 Primary Sources

2 MARKET OVERVIEW

2.1 Product Definition
2.2 Global Market Growth Prospects
  2.2.1 Global Drugs for Schistosomiasis Market Size (2019-2030) & (US$ Million)
  2.2.2 Global Drugs for Schistosomiasis Sales (2019-2030)
  2.2.3 Global Drugs for Schistosomiasis Market Average Price (2019-2030)
2.3 Drugs for Schistosomiasis by Type
  2.3.1 Market Value Comparison by Type (2019 VS 2023 VS 2030) & (US$ Million)
  2.3.2 Praziquantel
  2.3.3 Oxamniquine
  2.3.4 Other
2.4 Drugs for Schistosomiasis by Application
  2.4.1 Market Value Comparison by Application (2019 VS 2023 VS 2030) & (US$ Million)
  2.4.2 S. haematobium
  2.4.3 S. mansoni
  2.4.4 S. japonicum
  2.4.5 S. mekongi
  2.4.6 S. intercalatum

3 MARKET COMPETITIVE LANDSCAPE BY MANUFACTURERS

3.1 Global Drugs for Schistosomiasis Market Competitive Situation by Manufacturers (2019 Versus 2023)
3.2 Global Drugs for Schistosomiasis Sales (M Units) of Manufacturers (2019-2024)
3.3 Global Drugs for Schistosomiasis Revenue of Manufacturers (2019-2024)
3.4 Global Drugs for Schistosomiasis Average Price by Manufacturers (2019-2024)
3.5 Global Drugs for Schistosomiasis Industry Ranking, 2022 VS 2023 VS 2024
3.6 Global Manufacturers of Drugs for Schistosomiasis, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Drugs for Schistosomiasis, Product Type & Application
3.8 Global Manufacturers of Drugs for Schistosomiasis, Date of Enter into This Industry
3.9 Global Drugs for Schistosomiasis Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition

4 MANUFACTURERS PROFILED

4.1 Shin Poong
  4.1.1 Shin Poong Company Information
  4.1.2 Shin Poong Business Overview
  4.1.3 Shin Poong Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2019-2024)
  4.1.4 Shin Poong Drugs for Schistosomiasis Product Portfolio
  4.1.5 Shin Poong Recent Developments
4.2 Merck
  4.2.1 Merck Company Information
  4.2.2 Merck Business Overview
  4.2.3 Merck Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2019-2024)
  4.2.4 Merck Drugs for Schistosomiasis Product Portfolio
  4.2.5 Merck Recent Developments
4.3 Bayer
  4.3.1 Bayer Company Information
  4.3.2 Bayer Business Overview
  4.3.3 Bayer Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2019-2024)
  4.3.4 Bayer Drugs for Schistosomiasis Product Portfolio
  4.3.5 Bayer Recent Developments
4.4 EIPICO
  4.4.1 EIPICO Company Information
  4.4.2 EIPICO Business Overview
  4.4.3 EIPICO Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2019-2024)
  4.4.4 EIPICO Drugs for Schistosomiasis Product Portfolio
  4.4.5 EIPICO Recent Developments
4.5 Chandra Bhagat Pharma
  4.5.1 Chandra Bhagat Pharma Company Information
  4.5.2 Chandra Bhagat Pharma Business Overview
  4.5.3 Chandra Bhagat Pharma Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2019-2024)
  4.5.4 Chandra Bhagat Pharma Drugs for Schistosomiasis Product Portfolio
  4.5.5 Chandra Bhagat Pharma Recent Developments
4.6 Taj Pharmaceuticals
  4.6.1 Taj Pharmaceuticals Company Information
  4.6.2 Taj Pharmaceuticals Business Overview
  4.6.3 Taj Pharmaceuticals Drugs for Schistosomiasis Sales, Revenue and Gross Margin (2019-2024)
  4.6.4 Taj Pharmaceuticals Drugs for Schistosomiasis Product Portfolio
  4.6.5 Taj Pharmaceuticals Recent Developments

5 GLOBAL DRUGS FOR SCHISTOSOMIASIS MARKET SCENARIO BY REGION

5.1 Global Drugs for Schistosomiasis Market Size by Region: 2019 VS 2023 VS 2030
5.2 Global Drugs for Schistosomiasis Sales by Region: 2019-2030
  5.2.1 Global Drugs for Schistosomiasis Sales by Region: 2019-2024
  5.2.2 Global Drugs for Schistosomiasis Sales by Region: 2025-2030
5.3 Global Drugs for Schistosomiasis Revenue by Region: 2019-2030
  5.3.1 Global Drugs for Schistosomiasis Revenue by Region: 2019-2024
  5.3.2 Global Drugs for Schistosomiasis Revenue by Region: 2025-2030
5.4 North America Drugs for Schistosomiasis Market Facts & Figures by Country
  5.4.1 North America Drugs for Schistosomiasis Market Size by Country: 2019 VS 2023 VS 2030
  5.4.2 North America Drugs for Schistosomiasis Sales by Country (2019-2030)
  5.4.3 North America Drugs for Schistosomiasis Revenue by Country (2019-2030)
  5.4.4 U.S.
  5.4.5 Canada
5.5 Europe Drugs for Schistosomiasis Market Facts & Figures by Country
  5.5.1 Europe Drugs for Schistosomiasis Market Size by Country: 2019 VS 2023 VS 2030
  5.5.2 Europe Drugs for Schistosomiasis Sales by Country (2019-2030)
  5.5.3 Europe Drugs for Schistosomiasis Revenue by Country (2019-2030)
  5.5.4 Germany
  5.5.5 France
  5.5.6 U.K.
  5.5.7 Italy
  5.5.8 Russia
5.6 Asia Pacific Drugs for Schistosomiasis Market Facts & Figures by Country
  5.6.1 Asia Pacific Drugs for Schistosomiasis Market Size by Country: 2019 VS 2023 VS 2030
  5.6.2 Asia Pacific Drugs for Schistosomiasis Sales by Country (2019-2030)
  5.6.3 Asia Pacific Drugs for Schistosomiasis Revenue by Country (2019-2030)
  5.6.4 China
  5.6.5 Japan
  5.6.6 South Korea
  5.6.7 India
  5.6.8 Australia
  5.6.9 China Taiwan
  5.6.10 Indonesia
  5.6.11 Thailand
  5.6.12 Malaysia
5.7 Latin America Drugs for Schistosomiasis Market Facts & Figures by Country
  5.7.1 Latin America Drugs for Schistosomiasis Market Size by Country: 2019 VS 2023 VS 2030
  5.7.2 Latin America Drugs for Schistosomiasis Sales by Country (2019-2030)
  5.7.3 Latin America Drugs for Schistosomiasis Revenue by Country (2019-2030)
  5.7.4 Mexico
  5.7.5 Brazil
  5.7.6 Argentina
5.8 Middle East and Africa Drugs for Schistosomiasis Market Facts & Figures by Country
  5.8.1 Middle East and Africa Drugs for Schistosomiasis Market Size by Country: 2019 VS 2023 VS 2030
  5.8.2 Middle East and Africa Drugs for Schistosomiasis Sales by Country (2019-2030)
  5.8.3 Middle East and Africa Drugs for Schistosomiasis Revenue by Country (2019-2030)
  5.8.4 Turkey
  5.8.5 Saudi Arabia
  5.8.6 UAE

6 SEGMENT BY TYPE

6.1 Global Drugs for Schistosomiasis Sales by Type (2019-2030)
  6.1.1 Global Drugs for Schistosomiasis Sales by Type (2019-2030) & (M Units)
  6.1.2 Global Drugs for Schistosomiasis Sales Market Share by Type (2019-2030)
6.2 Global Drugs for Schistosomiasis Revenue by Type (2019-2030)
  6.2.1 Global Drugs for Schistosomiasis Sales by Type (2019-2030) & (US$ Million)
  6.2.2 Global Drugs for Schistosomiasis Revenue Market Share by Type (2019-2030)
6.3 Global Drugs for Schistosomiasis Price by Type (2019-2030)

7 SEGMENT BY APPLICATION

7.1 Global Drugs for Schistosomiasis Sales by Application (2019-2030)
  7.1.1 Global Drugs for Schistosomiasis Sales by Application (2019-2030) & (M Units)
  7.1.2 Global Drugs for Schistosomiasis Sales Market Share by Application (2019-2030)
7.2 Global Drugs for Schistosomiasis Revenue by Application (2019-2030)
  7.2.1 Global Drugs for Schistosomiasis Sales by Application (2019-2030) & (US$ Million)
  7.2.2 Global Drugs for Schistosomiasis Revenue Market Share by Application (2019-2030)
7.3 Global Drugs for Schistosomiasis Price by Application (2019-2030)

8 VALUE CHAIN AND SALES CHANNELS ANALYSIS OF THE MARKET

8.1 Drugs for Schistosomiasis Value Chain Analysis
  8.1.1 Drugs for Schistosomiasis Key Raw Materials
  8.1.2 Raw Materials Key Suppliers
  8.1.3 Drugs for Schistosomiasis Production Mode & Process
8.2 Drugs for Schistosomiasis Sales Channels Analysis
  8.2.1 Direct Comparison with Distribution Share
  8.2.2 Drugs for Schistosomiasis Distributors
  8.2.3 Drugs for Schistosomiasis Customers

9 GLOBAL DRUGS FOR SCHISTOSOMIASIS ANALYZING MARKET DYNAMICS

9.1 Drugs for Schistosomiasis Industry Trends
9.2 Drugs for Schistosomiasis Industry Drivers
9.3 Drugs for Schistosomiasis Industry Opportunities and Challenges
9.4 Drugs for Schistosomiasis Industry Restraints

10 REPORT CONCLUSION

11 DISCLAIMER



More Publications